Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury.
classical Hodgkin lymphoma
fibroblasts
gene expression analysis
luteolin
methylation profiling
nodular sclerosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
06
10
2019
revised:
24
10
2019
accepted:
25
10
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
epublish
Résumé
Classical Hodgkin lymphoma (cHL) is one of the most common malignant lymphomas in Western Europe. The nodular sclerosing subtype of cHL (NS cHL) is characterized by a proliferation of fibroblasts in the tumor microenvironment, leading to fibrotic bands surrounding the lymphoma infiltrate. Several studies have described a crosstalk between the tumour cells of cHL, the Hodgkin- and Reed-Sternberg (HRS) cells, and cancer-associated fibroblasts. However, to date a deep molecular characterization of these fibroblasts is lacking. Thus, the aim of the present study is a comprehensive characterization of these fibroblasts. Gene expression profiling and methylation profiles of fibroblasts isolated from primary lymph node suspensions revealed persistent differences between fibroblasts obtained from NS cHL and lymphadenitis. NS cHL derived fibroblasts exhibit a myofibroblastic phenotype characterized by myocardin (
Identifiants
pubmed: 31671543
pii: cancers11111687
doi: 10.3390/cancers11111687
pmc: PMC6896072
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : HA6145/2-1, HE 3552/4-2, HA 1284/7-2, KU1315/9-2
Références
Br J Haematol. 2011 Jan;152(2):182-90
pubmed: 21114485
PLoS One. 2012;7(8):e44052
pubmed: 22937150
Leuk Lymphoma. 2014 Jan;55(1):149-59
pubmed: 23647062
Int J Cancer. 2003 Nov 1;107(2):197-201
pubmed: 12949794
Leuk Lymphoma. 1992 Jul;7(4):297-303
pubmed: 1493429
Am J Pathol. 1993 Jan;142(1):11-6
pubmed: 8424449
Blood. 2008 Feb 15;111(4):2339-46
pubmed: 18070985
Diagn Pathol. 2013 Jul 02;8:110
pubmed: 23819566
Histopathology. 2013 Mar;62(4):632-41
pubmed: 23379820
Oncogene. 2011 Dec 8;30(49):4874-86
pubmed: 21625222
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Mediators Inflamm. 2014;2014:292376
pubmed: 24523569
Nat Rev Cancer. 2017 Jan;17(1):38-53
pubmed: 27932800
Oncotarget. 2017 Mar 7;8(10):16463-16472
pubmed: 28145886
Histopathology. 2001 Apr;38(4):368-75
pubmed: 11318902
Int J Cancer. 2019 Sep 15;145(6):1538-1546
pubmed: 30801698
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
J Pathol. 2010 Jul;221(3):248-63
pubmed: 20527019
Leuk Lymphoma. 1994 Sep;15(1-2):33-43
pubmed: 7858501
Am J Surg Pathol. 2013 Aug;37(8):1173-81
pubmed: 23648461
J Pathol. 2014 Mar;232(4):405-14
pubmed: 24659185
J Biomed Sci. 1995 Oct;2(4):302-313
pubmed: 11725067
J Biomed Res. 2015 Jan;29(1):3-19
pubmed: 25745471
PLoS One. 2017 May 15;12(5):e0177378
pubmed: 28505189
Int J Mol Sci. 2016 Jun 09;17(6):
pubmed: 27294919
PLoS One. 2014 Oct 01;9(10):e109208
pubmed: 25272043
Cell Rep. 2012 Sep 27;2(3):568-79
pubmed: 22999938
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Cell Immunol. 2001 Jul 10;211(1):37-42
pubmed: 11585386
Stem Cell Rev Rep. 2017 Apr;13(2):258-266
pubmed: 28154962
Annu Rev Pathol. 2009;4:151-74
pubmed: 19400691
Oncotarget. 2016 Nov 1;7(44):72197-72210
pubmed: 27708232
Int J Cancer. 2008 Feb 15;122(4):769-76
pubmed: 17935139
Nat Cell Biol. 2014 Sep;16(9):889-901
pubmed: 25150980
Cancer Lett. 2016 Sep 28;380(1):243-52
pubmed: 26474544
Leukemia. 2012 Aug;26(8):1812-20
pubmed: 22460735
Leuk Lymphoma. 2012 Feb;53(2):195-201
pubmed: 21756027
Br J Haematol. 2011 Oct;155(1):53-64
pubmed: 21749361
Int Immunol. 2008 Dec;20(12):1483-7
pubmed: 18824503
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
J Clin Invest. 2012 Oct;122(10):3439-47
pubmed: 23023715
Lab Invest. 2017 Dec;97(12):1412-1426
pubmed: 29035375
Leuk Lymphoma. 2017 Aug;58(8):1922-1930
pubmed: 27919179
Int J Cancer. 2009 Sep 1;125(5):1092-101
pubmed: 19391137